Arkolith/Insider Trading/RXDX/Form 4

Marshall Keith W

Chief Financial OfficerPrometheus Biosciences, Inc. (RXDX) · full profile →Form 4 · filed Jun 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 2, 2023Option exercise(M)78K$3.10$242K88K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 2, 2023Option exercise(M)78K—$053K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-034038) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML